Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention - 21/08/11

Paul W. Armstrong, MD ^a, ⁎ , Peter X. Adams, MD ^b, Hussein R. Al-Khalidi, PhD ^f, Christian Hamm, MD ^c, David Holmes, MD ^d, William O'Neill, MD ^e, Thomas G. Todaro, MD ^f, Alec Vahanian, MD ^g, Frans Van de Werf, MD ^h, Christopher B. Granger, MD ⁱ

on behalf of the APEX-AMI Steering Committee

^a Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 

^b Alexion Pharmaceuticals 

^c Kerckhoff Heart Center, Bad Nauheim, Germany 

^d Mayo Clinic, Rochester, Minn 

^e Beaumont Heart Center, Royal Oak, Mich 

^f Procter & Gamble Pharmaceuticals 

^g Hopital Bichat, Paris, France 

^h University Hospital Gasthuisberg, Leuven, Belgium 

ⁱ Duke Clinical Research Institute, Durham, NC 

 Reprint requests: Paul W. Armstrong, MD, Department of Medicine, Division of Cardiology, University of Alberta, 2-51 Medical Sciences Building, Edmonton, Alberta, Canada T6G 2H7.